-
Aug 8, 2024 | 
hcplive.com | Saakshi Khattri |Jennifer Soung |Kostas N. Botsoglou
August 8, 2024By Medical experts engage in a discussion surrounding the treatment and management of patients diagnosed with psoriasis and psoriatic arthritis.
-
Jul 29, 2024 | 
hcplive.com | Saakshi Khattri |Jennifer Soung |Kostas N. Botsoglou
July 29, 2024By Dermatologic experts explore strategies to slow the progression of psoriasis to psoriatic arthritis, offering evidence-based insights to optimize patient outcomes and enhance long-term disease management. Related Content Integrating Dry Eye Care Within Ophthalmic Surgery PracticeLaura Periman, MD;Kelly Nichols, OD;Alice Epitropoulos, MDJuly 1st 2024PodcastAddressing Suboptimal Anti-VEGF Response in Neovascular AMD and DMEHong-Uyen Hua, MD;Sruthi Arepalli, MD;Rishi P.
-
Jul 29, 2024 | 
consultantlive.com | Saakshi Khattri |Jennifer Soung |Kostas N. Botsoglou
Targeting Disease Modification in Psoriasis and Psoriatic ArthritisPublished on: July 29, 2024Dermatologic experts explore strategies to slow the progression of psoriasis to psoriatic arthritis, offering evidence-based insights to optimize patient outcomes and enhance long-term disease management.
-
May 10, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 10, 2024Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The conversation delves into various educational resources utilized both by healthcare providers and patients regarding ddalimumab biosimilars.
-
May 10, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 10, 2024Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.
-
May 10, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 10, 2024Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The dialogue revolves around patient education regarding biosimilar medications, focusing on common questions and concerns raised by patients and healthcare providers.
-
May 3, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 3, 2024Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.
-
May 3, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 3, 2024Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The discussion centers on how healthcare professionals can promote the use of adalimumab biosimilars and enhance patient care.
-
Apr 29, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
April 29, 2024Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The discussion revolves around experiences initiating patients on biosimilars.
-
Apr 29, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. An expert discusses the safe transition of patients from a reference product to a biosimilar. He emphasizes that although biosimilars may not be identical, they are sufficiently similar in every parameter.
